Virax Biolabs Group Limited (VRAX)

Market Cap	3.32M
Revenue (ttm)	6,331
Net Income (ttm)	-6.06M
Shares Out	4.34M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,742
Open	0.7599
Previous Close	0.7412
Day's Range	0.7509 - 0.7800
52-Week Range	0.7222 - 7.6300
Beta	1.64
Analysts	Strong Buy
Price Target	3.00 (+292.16%)
Earnings Date	n/a

About VRAX

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women’s health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also prov...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 21, 2022
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: VRAX
• Website: https://viraxbiolabs.com

Financial Performance

In 2024, Virax Biolabs Group's revenue was $6,331, a decrease of -95.95% compared to the previous year's $156,419. Losses were -$6.06 million, -9.98% less than in 2023.

Analyst Summary

According to one analyst, the rating for VRAX stock is "Strong Buy" and the 12-month stock price target is $3.0.

Price Target

$3.0

(292.16% upside)

Analyst Consensus: Strong Buy